Q1 Earnings Estimate for Longeveron Issued By Roth Capital

Longeveron Inc. (NASDAQ:LGVN) – Roth Capital raised their Q1 2025 earnings per share estimates for Longeveron in a research note issued on Monday, March 3rd. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($0.30) for the quarter, up from their prior estimate of ($0.36). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.40) EPS.

A number of other research firms also recently commented on LGVN. Roth Mkm assumed coverage on Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Longeveron in a research note on Monday.

Longeveron Stock Performance

NASDAQ:LGVN opened at $1.44 on Thursday. The company has a market capitalization of $21.37 million, a price-to-earnings ratio of -0.23 and a beta of 0.37. Longeveron has a one year low of $0.77 and a one year high of $6.40. The stock has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $1.89.

Hedge Funds Weigh In On Longeveron

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp acquired a new position in Longeveron in the third quarter valued at approximately $29,000. Northern Trust Corp acquired a new position in Longeveron in the fourth quarter valued at approximately $31,000. Jane Street Group LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $35,000. Virtu Financial LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $53,000. Finally, Geode Capital Management LLC boosted its stake in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the period. 10.01% of the stock is currently owned by institutional investors and hedge funds.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.